Pharma Pulse 1/6/25: The Future of RFID and Supply Chain Management, Optimizing IBD Management & more

Peer Exchange: The Future of RFID and Supply Chain Management (Episode 6)

In the final part of this roundtable discussion, a panel of subject matter experts discuss what the future holds for this technology, why end-to-end visibility is necessary in healthcare, and the opportunities for greater RFID adoption that lie ahead.

Optimizing Inflammatory Bowel Disease Management: The Value of Integrated Pharmacists in Modern Health Care

Adherence to thiopurine medications after 6 months of use was 87.9% under direct pharmacist care but 65.7% under general practitioner guidance.

US Treasury Is Latest Victim of Most ‘Persistent’ Hacking Threat

A growing roster of political figures, US government agencies and companies that provide critical services have one thing in common: They have allegedly been hacked by China.

The latest victim is the US Treasury Department, which disclosed that Chinese state-sponsored hackers had breached its network via a third-party provider, accessing some unclassified documents.

Analyzing the Future of Microscopy

The "Microscopy: Global Market" report has been added to ResearchAndMarkets.com's offering.

The Global Microscopy Market was valued at USD 9.7 Billion in 2024, and is expected to reach USD 13.3 Billion by 2029, rising at a CAGR of 6.60%.

The scope of this study encompasses an analysis of the global microscopy market. The Research evaluates it based on product type, which includes microscope types and accessories and supplies. The market is also analyzed based on application. The Research determines the current market status in each segment, examines its impact on future needs and presents growth forecasts over the next five years.

Lowenstein Sandler LLP on LinkedIn

Lowenstein FDA Regulatory Practice Chair Jim Shehan is featured in Pharmaceutical Executive's "2024's Biggest Weight Loss Drug Stories," where his interview explored critical topics such as FDA and regulatory responses to GLP-1 drugs, strategies for addressing public interest and off-label use, pathways to ensure coverage for GLP-1 medications, and guidance for investors and financiers entering the weight-loss medication market.

Read the full article: https://bit.ly/4gAvQ1B
Read Jim’s bio: https://lnkd.in/dfVXMGeP

#weightlossdrugs #pharmaceuticalindustry #glp1 #healthpolicy #drugdevelopment

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs